Literature DB >> 14680965

High-level expression and one-step purification of recombinant dengue virus type 2 envelope domain III protein in Escherichia coli.

Smita Jaiswal1, Navin Khanna, Sathyamangalam Swaminathan.   

Abstract

Dengue virus infection poses a serious global public health threat for which there is currently no therapy or a licensed vaccine. The domain III of the dengue virus encoded envelope protein, which carries multiple conformation-dependent neutralizing epitopes, is critical for virus infectivity. We have expressed and purified recombinant domain III of dengue virus type-2 envelope, without the aid of a carrier protein in Escherichia coli. A 6x His tag was inserted at the N terminus to facilitate its one-step purification. The protein was overexpressed in the form of insoluble inclusion bodies, which were solubilized under highly denaturing conditions and then subjected to a previously optimized arginine-mediated renaturation protocol. We purified recombinant domain III protein to near homogeneity by Ni-NTA affinity chromatography and obtained yields of approximately 30 mg/L. The purified protein was recognized in Western analyses by monoclonal antibodies specific for the 6x His tag as well as the 3H5 neutralizing epitope known to reside in domain III. The authenticity of the recombinant protein was also verified in a sandwich ELISA designed to specifically and simultaneously identify the 6x His tag and the 3H5 epitope. In addition, murine and human polyclonal sera also recognized the recombinant protein. The in vitro refolded recombinant protein preparation was biologically functional. It could effectively protect cells in culture against dengue virus type-2 infection, apparently by blocking the virus from binding to host cells. This expression/purification strategy has the potential for inexpensive scale-up and may prove to be useful for dengue diagnostics and vaccine development efforts.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14680965     DOI: 10.1016/j.pep.2003.09.009

Source DB:  PubMed          Journal:  Protein Expr Purif        ISSN: 1046-5928            Impact factor:   1.650


  24 in total

1.  Single antigen detects both immunoglobulin M (IgM) and IgG antibodies elicited by all four dengue virus serotypes.

Authors:  Menaka D Hapugoda; Gaurav Batra; W Abeyewickreme; S Swaminathan; N Khanna
Journal:  Clin Vaccine Immunol       Date:  2007-09-26

Review 2.  Fight against dengue in India: progresses and challenges.

Authors:  Bhavna Gupta; B P Niranjan Reddy
Journal:  Parasitol Res       Date:  2013-02-28       Impact factor: 2.289

3.  Overexpression and purification of folded domain of prostate cancer related proteins MSMB and PSA.

Authors:  Mohini Tiwary; Nipanshu Agarwal; Amit Dinda; Subhash C Yadav
Journal:  Mol Biol Rep       Date:  2016-04-01       Impact factor: 2.316

4.  Production of dengue virus envelope protein domain III-based antigens in tobacco chloroplasts using inducible and constitutive expression systems.

Authors:  Johanna Gottschamel; Andreas Lössl; Stephanie Ruf; Yanliang Wang; Morten Skaugen; Ralph Bock; Jihong Liu Clarke
Journal:  Plant Mol Biol       Date:  2016-04-26       Impact factor: 4.076

5.  Recombinant multiepitope protein for early detection of dengue infections.

Authors:  Ravulapalli Anandarao; Sathyamangalam Swaminathan; Sirimali Fernando; Asha M Jana; Navin Khanna
Journal:  Clin Vaccine Immunol       Date:  2006-01

6.  Humanized monoclonal antibodies derived from chimpanzee Fabs protect against Japanese encephalitis virus in vitro and in vivo.

Authors:  Ana P Goncalvez; Cheng-Hsin Chien; Kamolchanok Tubthong; Inna Gorshkova; Carrie Roll; Olivia Donau; Peter Schuck; Sutee Yoksan; Sy-Dar Wang; Robert H Purcell; Ching-Juh Lai
Journal:  J Virol       Date:  2008-05-14       Impact factor: 5.103

Review 7.  Dengue and dengue haemorrhagic fever: Indian perspective.

Authors:  U C Chaturvedi; Rachna Nagar
Journal:  J Biosci       Date:  2008-11       Impact factor: 1.826

8.  Amino acid starvation enhances vaccine efficacy by augmenting neutralizing antibody production.

Authors:  Sumbul Afroz; Srikanth Battu; Shaikh Matin; Sabrina Solouki; Jessica P Elmore; Gillipsie Minhas; Weishan Huang; Avery August; Nooruddin Khan
Journal:  Sci Signal       Date:  2019-11-12       Impact factor: 8.192

9.  DNA vaccines against dengue virus type 2 based on truncate envelope protein or its domain III.

Authors:  Adriana S Azevedo; Anna M Y Yamamura; Marcos S Freire; Gisela F Trindade; Myrna Bonaldo; Ricardo Galler; Ada M B Alves
Journal:  PLoS One       Date:  2011-07-11       Impact factor: 3.240

Review 10.  Dengue in India.

Authors:  Nivedita Gupta; Sakshi Srivastava; Amita Jain; Umesh C Chaturvedi
Journal:  Indian J Med Res       Date:  2012-09       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.